Vivos Therapeutics (VVOS) News Today $5.18 +0.85 (+19.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.18 0.00 (-0.10%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Vivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30 at 10:47 AM | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 15, 2025 | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 14, 2025 | globenewswire.comVivos Therapeutics announces agreement to acquire operating assets of SCNApril 17, 2025 | markets.businessinsider.comVivos Opens New Sleep CenterApril 16, 2025 | baystreet.caVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaApril 16, 2025 | globenewswire.comVivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global PartnersApril 2, 2025 | markets.businessinsider.comVivos Therapeutics’ Earnings Call Highlights Growth and ExpansionApril 1, 2025 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateMarch 31, 2025 | globenewswire.com4VVOS : Earnings Outlook For Vivos TherapeuticsMarch 28, 2025 | benzinga.comVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallMarch 28, 2025 | globenewswire.comVivos Therapeutics expands strategic alliance with Rebis HealthFebruary 25, 2025 | markets.businessinsider.comVivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions NationwideFebruary 24, 2025 | markets.businessinsider.comVivos Therapeutics sees strong adoption of OSA treatment, expands strategic allianceFebruary 24, 2025 | proactiveinvestors.comVivos Therapeutics Enters Market Offering Agreement with WainwrightFebruary 14, 2025 | tipranks.comVivos Therapeutics files $50M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comVivos Therapeutics files to sell 854,332 shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comVivos to sell 709,220 shares at $4.935 in registered direct offeringDecember 23, 2024 | markets.businessinsider.comVivos Therapeutics announces funding boostDecember 23, 2024 | proactiveinvestors.comVivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesDecember 23, 2024 | globenewswire.comVivos Therapeutics price target lowered to $6 from $8.25 at Alliance Global PartnersNovember 19, 2024 | markets.businessinsider.comVivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 16, 2024 | finance.yahoo.comVivos Therapeutics Reports Revenue Growth and Strategic MilestonesNovember 16, 2024 | markets.businessinsider.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comVivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateNovember 15, 2024 | markets.businessinsider.comVivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comVivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference CallNovember 13, 2024 | globenewswire.comInvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical DevicesOctober 9, 2024 | msn.comVivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatmentOctober 8, 2024 | proactiveinvestors.comVivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical AssociationOctober 8, 2024 | globenewswire.comTinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct OfferingSeptember 20, 2024 | msn.com Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address VVOS Media Mentions By Week VVOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVOS News Sentiment▼0.800.63▲Average Medical News Sentiment VVOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVOS Articles This Week▼21▲VVOS Articles Average Week Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lucid Diagnostics News Today Anteris Technologies Global News Today Microbot Medical News Today icad News Today Jin Medical International News Today Fonar News Today Apyx Medical News Today Vivani Medical News Today Nutriband News Today Fractyl Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVOS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.